Repro Med Systems Inc
NASDAQ:KRMD
Repro Med Systems Inc
Repro-Med Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. The company is headquartered in Chester New York, New York and currently employs 77 full-time employees. The company is focused on the developing, manufacturing, and commercializing of specialty infusion solutions. The firm's products include the FREEDOM Infusion Systems, which consist of the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgHFlo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The FREEDOM System operates at a lower pressure and maintains a balance between what a patient’s subcutaneous tissues can absorb and what the system delivers. The firm performs product assembly, calibration, pre- and post-assembly quality control inspection and testing, and final packaging for all its products at its Chester, New York facility.
Repro-Med Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. The company is headquartered in Chester New York, New York and currently employs 77 full-time employees. The company is focused on the developing, manufacturing, and commercializing of specialty infusion solutions. The firm's products include the FREEDOM Infusion Systems, which consist of the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgHFlo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The FREEDOM System operates at a lower pressure and maintains a balance between what a patient’s subcutaneous tissues can absorb and what the system delivers. The firm performs product assembly, calibration, pre- and post-assembly quality control inspection and testing, and final packaging for all its products at its Chester, New York facility.
Record Revenue: KORU reported its second consecutive quarter with over $10 million in revenue, growing 27% year-over-year, driven by strong international and core SCIg business performance.
Guidance Raised: The company increased its full-year 2025 revenue guidance to $40.5–$41 million, up from $39.5–$40.5 million, reflecting 20%–22% annual growth.
Margin Performance: Gross margin remained strong at 60.2%, though down 320 basis points year-over-year due to manufacturing costs and geographic mix; full-year gross margin guidance of 61%–63% was reaffirmed.
International Surge: International revenue grew 230% this quarter, partly due to stocking orders and successful prefilled syringe conversions in Europe, with market share gains targeted to reach the 40% range in coming years.
Oncology Progress: The company completed a positive U.S. oncology infusion pilot, with high nurse and patient satisfaction, and is preparing a 510(k) FDA submission for market entry in the second half of 2026.
Profitability and Cash: KORU achieved positive adjusted EBITDA, positive cash flow, and ended the quarter with $8.5 million in cash, projecting at least $8.2 million by year-end.
Pipeline Expansion: Multiple new pharmaceutical collaborations and product pipeline progress highlight ongoing growth opportunities, including future launches in oncology and rare diseases.
